ClinicalTrials.gg
TerminatedNCT03853811Updated Apr 11, 2022

Customized Orthosis for Children With Clubfoot

An interventional study of Ankle Foot Orthosis (AFO) in Congenital Talipes Equinovarus, sponsored by Medical College of Wisconsin. Terminated at 1 site in United States. Open to participants aged Up to 12 Months. Per ClinicalTrials.gov, last updated 2022-04-11.

Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Treatment

Why this study was terminated
Insufficient resources

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
Up to 12 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 10 studies in Clubfoot with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Clubfoot · United States.

Started
2019
the only one that year
No phase
3 of 10
1 open now
Registered
8th of 10
by date
Lead sponsor
1 of 10
Medical College of Wisconsin

Among the 10 studies in Clubfoot with a site in United States, this one is the only one that started in 2019, is one of 3 with no phase, and was the 8th registered.

Clubfoot

69 studies on the registry are indexed under Clubfoot; 15 are open to participants now.

Browse Clubfoot studies →

Open to participants now

2 of the 10 studies in Clubfoot with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Clubfoot studies recruiting now, none (0%) set no upper age limit and 10 (100%) stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: Up to 12 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Clubfoot with a site in United States, or all of them as a file.
02

Study summary

This study will examine the use of a novel customized Ankle Foot Orthosis (AFO), created using 3D scanning, with children being treated for clubfoot. The AFO is inserted in the standard Mitchell shoe during bracing, following Ponseti casting. The investigators hypothesize that following Ponseti casting, the implementation of customized AFOs with Ponseti bracing will improve patient compliance and functional outcomes as well as lead to fewer relapses in comparison to the standard bracing with Mitchell shoes.

03

Conditions studied

  • Congenital Talipes Equinovarus

Browse trials for

04

Who can participate

Ages eligible
Up to 12 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • less than 12 months old (no age minimum)
  • no neuromuscular disease involved
  • treated by Ponseti casting
  • idiopathic bilateral or unilateral clubfoot
  • no other congenital foot deformity
  • no previous open surgeries to treat the deformity

Exclusion criteria

Exclusion Criteria:

  • patients with prior surgical treatment
  • not treated by Ponseti casting
  • an underlying syndrome
  • neurological disorder
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Mitchell Shoe + AFO

    Group will receive standard Mitchell shoes along with the custom orthotic insert.

    Device: Ankle Foot Orthosis (AFO)

  • No intervention
    Standard Mitchell Shoe (Control - Standard Treatment)

    Group will receive standard treatment which includes bracing with standard Mitchell shoes (no custom orthotic). Patients would receive this treatment regardless of study participation.

Interventions

  • DeviceAnkle Foot Orthosis (AFO)

    The intervention group will receive the custom AFO to use in their standard Mitchell shoe.

06

What researchers measure

Primary outcomes

  1. Assessment of Functional Outcomes of Bracing Treatment Using Dimeglio Scores

    Assessed using changes in Dimeglio Scores. The Dimeglio scoring system uses a 20-point system (20 being the most severe and \<5 as benign) by assessing four parameters. The severity of the deformity is then assigned a grade of I-IV with IV being the most severe. (A score of \<5 is given a grade of I, =5\<10 is grade II, =10\<15 is grade III, and =15\<20 is grade IV)

    Time frame: Collected when visit where cast is applied, visit when cast is removed, then at 2 weeks, 12 weeks, 24 weeks of bracing

  2. Time Spent in Brace to Assess Brace Compliance

    Measured with sensor placed in Mitchell shoe

    Time frame: 24 weeks (from start of bracing treatment)

  3. Assessing Treatment Factors that Impact Brace Compliance with Parental Questionnaires

    Assessing reasons for poor compliance with parental questionnaires. The questionnaires ask questions about casting, occurrences of skin lesions, history of treatments, bracing information, reasons for not using brace, and brace slippage

    Time frame: 24 weeks (from start of bracing treatment)

Secondary outcomes

  1. Assessing Demographic Factors that Impact Brace Compliance with Parental Questionnaire

    The initial questionnaire asks questions about parental demographics to determine what factors may influence brace treatment compliance

    Time frame: 24 weeks (from start of bracing treatment)

07

Study locations

1 site
  • Children's Hospital of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Mar 2022, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2019
First posted
Feb 26, 2019
StartActual
Apr 17, 2019
Primary completionActual
Mar 2, 2022
CompletionActual
Mar 2, 2022
Last update
Apr 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03853811
Responsible party
Scott Van Valin (Assistant Professor, Medical College of Wisconsin) — Principal investigator
First posted
Feb 26, 2019
Start date
Apr 17, 2019
Primary completion
Mar 2, 2022
Completion
Mar 2, 2022
Last update
Apr 11, 2022

Study contacts

Scott Van Valin, MD
principal investigator · Medical College of Wisconsin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion